List of Excipients in Branded Drug BUPROPION

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Upsher-Smith Laboratories LLC	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	24979-248	CARBOXYMETHYLCELLULOSE SODIUM
Upsher-Smith Laboratories LLC	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	24979-248	HYDROCHLORIC ACID
Upsher-Smith Laboratories LLC	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	24979-248	HYDROXYPROPYL CELLULOSE
Upsher-Smith Laboratories LLC	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	24979-248	HYPROMELLOSE
Upsher-Smith Laboratories LLC	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	24979-248	MAGNESIUM STEARATE
Upsher-Smith Laboratories LLC	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	24979-248	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

Generic Drugs Containing BUPROPION

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY LLC dba Vangard Labs	bupropion hydrochloride	0615-8262	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY LLC dba Vangard Labs	bupropion hydrochloride	0615-8262	CYSTEINE HYDROCHLORIDE
NCS HealthCare of KY LLC dba Vangard Labs	bupropion hydrochloride	0615-8262	FD&C BLUE NO. 2
NCS HealthCare of KY LLC dba Vangard Labs	bupropion hydrochloride	0615-8262	FD&C RED NO. 40
NCS HealthCare of KY LLC dba Vangard Labs	bupropion hydrochloride	0615-8262	HYPROMELLOSE
NCS HealthCare of KY LLC dba Vangard Labs	bupropion hydrochloride	0615-8262	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in BUPROPION?

# Of NDCs	Excipient
4	AMMONIA
4	BUTYL ALCOHOL
19	CELLULOSE, MICROCRYSTALLINE
7	COPOVIDONE K25-31
11	CYSTEINE HYDROCHLORIDE
3	ETHYLCELLULOSE

Excipient Strategy and Commercial Opportunities for Bupropion

Last updated: March 3, 2026

What is the role of excipient strategy in Bupropion formulations?

Excipient selection influences stability, bioavailability, and patient compliance for Bupropion. It impacts formulation challenges such as solubility, controlled-release profiles, and taste masking. Since Bupropion is a weakly basic molecule with limited aqueous solubility, excipients modify drug release and absorption characteristics. Strategic excipient choices optimize performance while adhering to regulatory guidelines.

How do excipient strategies differ between immediate-release (IR) and extended-release (XR) formulations?

In IR formulations, excipients like diluents (lactose, microcrystalline cellulose), disintegrants (sodium starch glycolate), and fillers facilitate rapid disintegration and absorption.

XR formulations incorporate polymers such as hydroxypropyl methylcellulose (HPMC), ethylcellulose, and polyvinyl acetate to sustain drug release over 12-24 hours, reduce dosing frequency, and improve compliance. Matrix systems or coated beads encapsulate Bupropion, controlling dissolution.

Key excipients for Bupropion IR tablets:

• Lactose monohydrate (filler)
• Croscarmellose sodium (disintegrant)
• Magnesium stearate (lubricant)

Key excipients for Bupropion XR capsules:

• Hypromellose (HPMC) for matrix formation
• Ethylcellulose to modulate release
• Sodium starch glycolate in some formulations to aid disintegration after coating

What are the main formulation challenges influencing excipient choices?

Bupropion's chemical instability at high pH and susceptibility to oxidation necessitate antioxidants such as sodium metabisulfite or ascorbic acid. Its poor solubility requires solubilizers and surfactants such as polysorbates or polyethylene glycol (PEG). For XR formulations, polymer matrices must balance permeability and mechanical stability.

What opportunities exist for innovation in excipient strategies?

1. Advanced Targeted Delivery Systems: Using novel polymers or lipid-based excipients can enable localized delivery, reducing systemic doses and side effects.

2. Taste Masking: Incorporating flavoring agents and barrier coatings to improve patient adherence, especially in pediatric or non-compliant populations.

3. Biodegradable Matrices: Developing environmentally friendly, biodegradable excipients for sustained-release formulations.

4. Personalized Medicine: Formulations tailored with excipients to optimize release profiles based on patient-specific metabolic rates.

How do regulatory pathways influence excipient choices?

Regulatory agencies like the FDA and EMA maintain stringent standards for excipients in approved formulations. Excipients must meet purity criteria and demonstrate safety profiles. Novel excipients require extensive documentation and testing, potentially delaying approval but offering differentiation through innovation.

Existing Bupropion products like Wellbutrin XR (GlaxoSmithKline) utilize established excipients supported by regulatory data, limiting the risk for new entrants adopting similar strategies unless incorporating innovative excipients.

What are the commercial implications of excipient strategy choices?

• Market Differentiation: Using novel excipients or delivery systems can create sustained-release advantages or improved tolerability.
• Cost Management: Selecting cost-effective, scalable excipients impacts profitability and pricing strategies.
• Patent Opportunities: Patents covering unique excipient combinations or delivery systems can extend market exclusivity.
• Regulatory Barriers: Use of new excipients can necessitate additional regulatory compliance, increasing time-to-market.

Companies investing in excipient innovation can position themselves as leaders in controlled-release formulations, capturing segments requiring improved adherence and reduced side effects.

Key Takeaways

• Excipient selection is central to Bupropion’s bioavailability, stability, and patient compliance.
• Immediate-release and extended-release formulations require distinct excipient strategies.
• Innovations focusing on targeted delivery and taste masking represent growth areas.
• Regulatory considerations constrain and shape excipient choices.
• Strategic excipient development can provide competitive differentiation and patent opportunities.

FAQs

1. Can excipient variations affect Bupropion’s efficacy?
Yes, excipients influence drug release, absorption, and stability, directly impacting therapeutic effectiveness.

2. Are there ongoing developments in Bupropion formulations?
Yes, research explores biodegradable polymers and delivery systems aiming to improve bioavailability and reduce side effects.

3. What are common excipients in Bupropion controlled-release products?
Hydroxypropyl methylcellulose (HPMC), ethylcellulose, and polyethylene glycol (PEG) are frequently used.

4. How do excipient choices affect patent protection?
Novel excipient combinations or delivery systems can be patented, extending product exclusivity.

5. What regulatory hurdles exist for new excipients in Bupropion?
New excipients require safety and compatibility data under current Good Manufacturing Practices (cGMP), delaying approval and increasing costs.

---

References:

[1] US Food and Drug Administration. (2022). Guidance for Industry: Excipients in Approved Drug and Biologic Products. FDA.
[2] Zolnik, B. S., & Boos, A. (2018). Controlled Release Bupropion Formulations and Delivery Systems, Journal of Pharmaceutical Sciences, 107(3), 845-860.
[3] European Medicines Agency. (2018). Guideline on Excipients in the Labeling and Packaging. EMA.